During an 8-year period, 3,638 children from institutions of the Pediatric Oncology Group (POG) were diagnosed with acute lymphoblastic leukemia (ALL). Fifty-seven patients had Philadelphia chromosome-positive (Ph') ALL. Blast cells obtained at diagnosis from 13 of these 57 cases (23%) were also found to have partial or complete monosomy 7 (-7). This subgroup of children with Ph'/-7 ALL was comprised primarily of older males with early B-lineage ALL. Bone marrow specimens from six Ph'/-7 patients were studied further using the polymerase chain reaction and primers that flank the ALL, and chronic myelogenous leukemia breakpoints to determine the molecular characteristic of the 9;22 translocation. Rearrangements were detected in RNA from bone marrow and/or peripheral blood cells of six patients, al-TH ADVANCES in the molecular evaluation of W hematologic malignancies, it has been shown that Philadelphia chromosome (Ph')-positive acute lymphoblastic leukemia (ALL) is a heterogeneous group of disorders.'~2 Although the reciprocal translocation between chromosomes 9 and 22 is cytogenetically identical in cases of ALL and chronic myelogenous leukemia (CML), the translocations generally differ at the molecular In cases of CML and some cases of ALL the c-abl proto-oncogene on chromosome 9 joins to a 5.8-kb region on chromosome 22 known as the breakpoint cluster region (bcr), which lies within a larger gene known as BCR.4 This union produces a unique 8.5-kb mRNA and results in a characteristic 210-Kd protein, ~2 1 0 .~~~ However, in other cases of ALL the c-abl proto-oncogene fuses to chromosome 22 within the large BCR gene, but at a region 5' to the bcr, which results in a smaller mRNA transcript and a 190-Kd protein, ~1 9 0 . ' ,~ Both p210 and p190 are tyrosine phosphokinases, and, like 
many other tyrosine phosphokinases, are likely to play a critical role in the control of cell proliferation. ' In adults affected with ALL, 20% to 30% show the Ph'." In contrast, only 5% of children affected with ALL are Ph'-positive.'' Children with Ph' positive ALL typically have clinically aggressive disease and a less favorable prognosis as compared to those with Ph'-negative Monosomy 7 (-7) is a cytogenetic abnormality associated with a childhood myeloproliferative disorder, the -7 ~yndrome.'~~'~ In cases of ALL or CML, -7 is unusual.'. '6 Children with the -7 syndrome usually present with pancytopenia and hepatosplenomegaly, which frequently evolve into acute myeloblastic leukemia (AML).15,17.1x Long-term bone marrow cultures derived from patients with the -7 syndrome have demonstrated clonal proliferation of an early stem cell." Finally, the familial occurrence of the -7 syndrome has led Shannon et alZo to propose that a tumor suppressor gene may be involved, such that an inherited predisposition to cancer results from functional inactivation of one chromosome 7 allele, which is then unmasked by loss of the normal chromosome 7 homologue. They also showed that in two families with -7 syndrome the predisposing locus is not on the long arm of chromosome 7."
During the past 8 years, 57 children with Ph' ALL were identified through member institutions of the Pediatric Oncology Group (POG). Of these, 13 (23%) also had cytogenetic evidence of partial or complete -7. The purpose of this study is to identify and characterize the relationship between the t(9;22) and -7 in childhood ALL. The premise is that these cases of t(9;22)/-7 (Ph'/-7) ALL may prove to be a distinct subgroup of childhood ALL.
immunofluorescence were also performed on lymphoblasts from the blood and/or bone marrow from all patients.
Patients 1 and 2 were treated according to the POG ALinC 13 protocol (details of specific therapy have been reported previously)?' Briefly, vincristine and prednisone were used for induction therapy and maintenance therapy was standard. Patients 5 through 8, 10, 11, and 13 were treated according to the more recent POG ALinC 14 protocol, regimen C,I3 and patients 3,4,9, and 12 were treated on the POG ALinC 15 Pilot Study?* In the ALinC 14 protocol, vincristine, prednisone, and asparaginase were used for induction; intermediate-dose methotrexate and cytosine arabinoside, and prednisone plus vincristine were used for consolidation. The ALinC 15 Pilot Study included a four-drug induction and a consolidation course with intravenous 6-mercaptopurine, methotrexate, cytosine arabinoside, daunorubicin, and teniposide. Maintenance therapy in both studies was standard except for the addition of intramuscular methotrexate. Central nervous system preventative therapy using intrathecal drugs without irradiation was used in all regimens.
Each participating institution had approval for these protocols from their Institutional Review Boards. Informed consent was obtained from each patient, the parents, or both as appropriate for treatment and classification studies. Cytogenetic studies were performed at member institutions for patients on the ALinC 13 study. Structural and numerical abnormalities were noted and centrally reviewed. Samples of bone marrow from the patients on the ALinC 14 study were shipped by overnight courier to a central reference laboratory (University of Alabama at Birmingham). On arrival, cells were placed in fresh medium and subjected to short-term (24-hour) culture. Routine methods were used for culture harvest, slide preparation, and GTW-banding.= Chromosomes were identified and assigned according to An International System for Human Cytogenetic Nomenclature."
Identijication of translocation breakpoints by the polymerase chain reaction (PCR). Peripheral blood and bone marrow samples from six patients were obtained for further study. Four different oligonucleotides were used to perform the PCR. The ablX3 oligonucleotide sequence (5'-TTT CTC CAG ACT GTT GAC TGG-3') is complementary to a sequence within the third ab1 exon and was used to prime cDNA synthesis as the downstream primer in all PCRs. The ablX2 oligonucleotide sequence (5'-CCT TCA GCG GCC AGT AGC AT-3') is derived from the second ab1 exon; a 290-bp ablX2-ablX3 amplification product is formed from ab/ mRNA and both bcr-ab1 fusion mRNAs, and serves as an internal positive control for integrity of the RNA. The CML-bcr oligonucleotide sequence (5'-ACA GCA TTC CGC TGA CCA TC-3') originates from the second bcr exon; 399-bp and 324-bp CML-bcr ablX3 amplification products are formed from the bcr-ab1 fusion mRNAs characteristic of CML (two different size products are produced from alternative splicing).2s The ALLE2 oligonucleotide sequence (5'-CCC CAC CAC CTA CCG CAT GTT-3') comes from a 5' region in the bcr mRNA, bcr-ab1 fusion mRNAs characteristic of ALL yield a 506-bp ALLE2ablX2 amplification product. BuEy coat cells were isolated from peripheral blood or bone marrow by sedimentation, and total cellular RNA was prepared by acid guanidinium thiocyante-phenol-chloroform extraction. Total RNA (3 bg) was used to synthesize a cDNA with the oligonucleotide, a b m , as primer. The reverse transcription reaction mixture was divided into three parts, and individual PCRs were performed with ablX2labIX3, CML-bcrlablX3, and ALLE2IablX3.
The PCR was performed with an initial denaturation at 94°C for 3 minutes, followed by annealing at 55°C for 1 minute, and then extension at 72°C for 1 minute 30 seconds. After this initial cycle, Description oftherapy.
Informed consent.
Cytogenetic methods. 34 more cycles were performed for 1 minute at 94"C, 1 minute at 55"C, and 1 minute 30 seconds at 72°C. The PCR-amplified products were separated on a 1.8% agarose gel and then transferred to nylon membranes (Zeta Probe; BioRad Laboratories, Richmond, CA). Amplification products were detected with the radiolabeled oligonucleotide CML-ab1 (5' TAT GCT TAG AGT GTT ATC TCC ACT 3'), which detects all four possible amplification products, and were confirmed by direct sequencing. Blood samples from healthy volunteer donors and samples without DNA were used as negative controls for each reaction.
The ALinC 13 and 14 trials for newly diagnosed children with non-B, non-T ALL were stratified and randomized studies. Historically, because children with Ph' ALL have fared poorly, such cases were assigned to the most aggressive treatment regimen on each major study.
All surviving children treated on the ALinC 13 study have been followed up for at least 4 years. The follow-up period for ALinC 14 patients is comparatively short because this study opened in 1986. The method of Kaplan and Meier was used to construct life tables;6 with standard errors according to Pet0 et al." Event-free survival (EFS) was defined as the interval between study entry and induction failure, relapse, or death from any cause. P values were obtained by the logrank test."
Study design and statistical analysis.
RESULTS
Of the 3,638 patients, 2,519 had evaluable marrow karyotypes. The incidence of Ph' ALL during this time period was 2.3% of the analyzable cases. The incidence of -7 ALL (without Ph') during this time period was approximately 1%. Of the 57 patients with Ph' ALL, 13 (23%) had both the Ph' and partial or complete -7. Five patients (nos. 1, 2, 9, 11, and 13) showed partial loss of chromosome 7, in particular a loss of the short arm.
Additionally, patients 9 and 13 were missing part of 7q. Complete karyotypes are listed in Table 1 . The clinical characteristics of the 13 patients with Ph'/-7 ALL are listed in Table 2 . There were 2 females and 11 males; all but one were older than 9 years and the presenting signs and symptoms were nonspecific. One child had meningeal leukemia at diagnosis. Four patients had blasts with L1 morphology and seven cases had L2 morphology by the FAB classication. The median initial white blood cell (WBC) count was moderately elevated at 40.5 x 109/L. The median hemoglobin level and platelet count were 9.7 g/dL and 128 x 109/L, respectively. Results of immunophenotyping studies were characteristic of a B-lineage lymphoid leukemia in all cases; however, blast cells from four patients also expressed myeloid antigens (Table 3) . Table 4 compares the median WBC counts and several clinical characteristics of patients with Ph' ALL and those patients with Ph'/-7 ALL from the ALinC 14 study.
Results of analyses of the Ph' translocation by the PCR on peripheral blood cells from six of the patients are shown in The treatment outcome for each patient is shown in (logrank P = .081, comparing entire EFS curves), suggesting that patients with Ph' ALL and -7 have an inferior prognosis. A comparable group of patients without the Ph' chromosome had a 3-year EFS of 77% (SE = 4%).13
DISCUSSION
We have identified a distinct subgroup of childhood ALL a group of 13 children whose diagnostic marrow karyotypes had partial or complete -7 in addition to the t(9;22). These two karyotypic findings unexpectedly oc- For curred in nearly one fourth of Ph' ALL cases and were more than a chance occurrence. Other investigators have noted the simultaneous occurrence of both Ph' and -7 in case reports of adult patients with ALL28-30 but according to a reference catalog there are no prior series of this association in ~hildren.~' The Ph'/-7 subgroup, which included almost exclusively older males, differs from Ph' ALL without -7, where the age range is broad and a less prominent male predominance. Symptoms were not unusual in these patients. The symptoms were typical of acute leukemia and included primarily fever, fatigue, bone pain, and adenopathy.
%
In four of five cases that were partially monosomic, the same region of chromosome 7, the short arm, was deleted (7p-). In one case (patient 9) 7pter-7q22 was deleted. Numerous studies suggest that the pathogenesis of myeloid leukemias results from the loss of 7q." Moreover, these studies implicated the location of a tumor suppressor gene at band 7q21-q22.33 Our data suggest that a second putative tumor suppressor gene on 7p may be involved in the pathogenesis of leukemia in this particular subset of patients. Candidate genes of interest in the deleted region on 7p include interleukin-6, a B-cell stimulatory and differentiation factor, and inhibin A, a molecule with an indirect suppressive effect on hematopoietic progenitor cells.
Immunophenotyping studies showed a lymphoid lineage in all of our patients. Twelve cases expressed the common ALL antigen without T-cell markers, cytoplasmic Ig, or surface Ig. There was one case of pre-B cell ALL. However, lymphoblasts from 4 of 11 children tested also expressed the myeloid antigen CD13, suggesting that some cases of Ph'/-7 ALL may be biphenotypic, and that the oncogenic event occurred in an early hematopoietic progenitor cell. In contrast, only 14% of children with Ph' ALL express CD13. In addition CD34, a stem cell antigen, was expressed in all 11 Ph'/-7 cases tested. The Ph'/-7 lymphoblasts in our patients also differ from common ALL with respect to FAB morphology. Seven of 13 children (54%) exhibited L2 FAB morphology, although the incidence of L2 cases was only 22% in the ALinC 13 study." No cases of Ph'/-7 ALL appeared to involve the T lineage, although cases of Ph' ALL expressing T-cell immunophenotype have been observed. 13 Molecular characterization of the Ph' breakpoint by PCR analysis of peripheral blood cells and bone marrow identified the translocation breakpoints in all six cases examined, even though four were in hematologic remission. The youngest child (1 year old) with Ph'/-7 ALL was found to have the CML rearrangement, whereas the five other children had the ALL rearrangement.
Because there were no cases of AML with t(9;22) and -7 identified in the time period of the ALinC 13 and 14 studies, we speculate that -7 may provide a particular growth advantage to lymphoblasts in the presence of the Ph' and to myeloblasts in its absence. Of interest is patient 8, whose diagnostic karyotype was 46,XY,t(9;22)(q34;qll)/ 45,XY,-7, t(9;22)(q34;qll). Both clones contained the Ph', but only one clone had lost chromosome 7. This patient achieved a hematologic remission, but remained Ph'-positive by PCR analysis. On a subsequent analysis, this child's bone marrow sample contained 15% to 20% Ph'-positive metaphases, while the clone containing -7 remained absent. These findings suggest that the initial rearrangement was the (9;22) translocation, and that loss of chromosome 7 was a secondary event. Serial cytogenetic studies of similar children at the time of remission and relapse should provide further evidence to evaluate this hypothesis.
The high induction failure rate (31%) observed in this study is unusual for children with common ALL. During this time period children with Ph'-negative ALL had an induction failure rate of 4%, and children with Ph' ALL alone had an induction failure rate of 21%." Children with Ph1/-7 ALL have a median EFS of only 6 months, consistent with the aggressive nature of this leukemia. Of the four children who are alive, two had the Ph' breakpoint detected by PCR analysis of their peripheral blood samples, suggesting that they are not disease free. These patients will have to be observed closely for the possibility of overt relapse.
Overall, the EFS for children with Ph'/-7 ALL was worse than that of children with Ph'-negative ALL and for those children with Ph' ALL. Children with Ph' ALL are known to respond poorly to intensive therapy" but those with -7 in addition to the Ph' chromosome appear to fare even worse. New treatment strategies are needed for these children because this subgroup has a dismal prognosis. Bone marrow transplantation might be considered after initial induction of remission for patients with t(9;22) ALL with or without -7. Two patients in this series underwent unsuccessful transplants. One patient underwent allogeneic transplantion with persistent disease, a known high-risk factor. The other patient received an unrelated, T-celldepleted transplant that may have negated any beneficial graft-versus-leukemia effect.
Studies in vitro34 and in vivo35 suggest that acquisition of the neoplastic phenotype is often a multi-step process involving the interaction of tumor suppressor genes, which 
